Vion Pharmaceuticals Inc., of New Haven, Conn., received U.S. Patent No. 6,475,482 titled "Genetically Modified Tumor-Targeted Bacteria With Reduced Virulence." It provides method-of-use coverage for Tapet VNP20009, Vion's first-generation Salmonella bacteria anticancer vector being studied in Phase I trials.